Inhibrx Biosciences stock falls 1.62 percent on October 5
Inhibrx Biosciences stock fell 1.62 percent to USD 95.42 on October 5, 2026, after its Q2 2026 diluted loss of USD 2.34 per share missed the consensus estimate. The company continues to focus on its clinical pipeline, but high cash burn and the binary nature of biotechnology investments remain key valuation factors. Analysts maintain an average target price of USD 197.50, significantly higher than the current trading price.
Inhibrx updates pipeline data as analysts rate Inhibrx stock Moderate Buy
Inhibrx Biosciences updated its corporate presentation, highlighting pipeline progress, while analysts issued a "Moderate Buy" consensus despite varied valuation expectations. The company reported a Q2 2026 loss of USD 2.34 per share, missing estimates. Analysts have an average 12-month price target of USD 197.50, significantly above its current Nasdaq trading price, emphasizing the importance of clinical milestones over revenue.
Inhibrx Biosciences stock gets a Moderate Buy consensus at USD 197.50
Inhibrx Biosciences (INBX) has received a "Moderate Buy" consensus from six brokerages, with an average 12-month price target of USD 197.50, significantly higher than its current price of USD 96.99. This optimism stems from positive Phase 2 trial data for INBRX-106, which showed a 48.3 percent objective response rate. Despite missing Q2 2026 earnings estimates, the clinical results offer a clear catalyst for the stock, though financial performance remains a key factor.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Biosciences' CEO, Mark Lappe, invested over $3.6 million in company shares after a 17% stock drop, despite strong Phase 2 clinical data for INBRX-106 which showed a 48.3% objective response rate in head and neck cancer. This insider buying, combined with a 28% short interest in the stock and pending FDA action on ozekibart, suggests a high potential for a short squeeze and a valuation reset. The company also has a near-term catalyst with a potential FDA approval for ozekibart, which would provide a new revenue stream as the first systemic treatment for conventional chondrosarcoma.
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com
The article reports on a Form 4 filing for Inhibrx Biosciences Inc. for September 28, 2026. It notes that the company's stock symbol is INBX, which saw a 3.65% increase. The content is brief, primarily serving as an announcement of the filing.
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock
Inhibrx Biosciences CEO Mark Lappe recently purchased nearly $1 million worth of company stock across multiple transactions on September 25 and 28, 2026. These purchases occurred despite the stock being down 9% over the past week, though it has seen a 211% return over the past year. Analysts maintain price targets between $230 and $325, and the company recently reported positive Phase 2 trial results for its drug INBRX-106 in head and neck cancer.
Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock
Inhibrx Biosciences CEO Mark Lappe recently purchased nearly $1 million worth of company stock, acquiring shares on September 25 and 28, 2026, at prices ranging from $98.8659 to $101.702 per share. These transactions, made through the Lappe Family Trust, occurred despite the stock's recent 9% dip, though it has seen a 211% return over the past year. Analysts have price targets between $230 and $325, and the company recently reported positive Phase 2 trial results for its cancer drug INBRX-106.
Inhibrx Biosciences posts updated corporate presentation highlighting INBRX-106 and ozekibart clinical progress
Inhibrx Biosciences has released an updated investor presentation detailing positive clinical results for its drugs INBRX-106 and ozekibart. INBRX-106 showed strong interim Phase 2 data with improved durability and a planned Phase 2 expansion for potential accelerated approval, while ozekibart met its primary endpoint in a registrational trial for chondrosarcoma. The company furnished the presentation as an Exhibit 99.1 on its investor website on September 28, 2026.
Four purchases over two days: Inhibrx Biosciences (INBX) CEO's family trust bought 10,000 shares.
Inhibrx Biosciences CEO Mark P. Lappe's family trust purchased 10,000 common shares of INBX over two days, September 25 and 28, 2026. The shares were acquired in four separate transactions at weighted-average prices ranging from $98.8659 to $101.7020. This insider transaction was reported via a Form 4 filing, with no Rule 10b5-1 plan indicated, and reflects a positive sentiment for the company.
Form 4 Inhibrx Biosciences Inc For: 28 September By Investing.com
This article from Investing.com reports the filing of a Form 4 by Inhibrx Biosciences Inc. for activity on September 28. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders, such as officers, directors, or beneficial owners, whenever they trade stock in their own company. It indicates transactions in company stock by insiders of Inhibrx Biosciences Inc.
A bone cancer drug met its trial goal for Inhibrx Biosciences (INBX), delaying progression versus placebo.
Inhibrx Biosciences (INBX) announced positive clinical trial results for its drug ozekibart, which met its primary endpoint in a chondrosarcoma registrational trial by significantly prolonging median progression-free survival (PFS) to 5.52 months compared to 2.66 months for placebo. The company also presented promising data for INBRX-106 in head and neck squamous cell carcinoma, showing superior objective response rates and PFS when combined with pembrolizumab. These developments highlight potential accelerated approval pathways and significant market opportunities for both drug candidates.
Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock
Jon Faiz Kayyem, a director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), recently purchased 5,000 shares of common stock for $100.00 per share, totaling $500,000. This transaction occurred on September 23, 2026, with the stock trading near $100 after a significant 247% gain over the past year. The purchase details reveal Kayyem's indirect beneficial ownership across several trusts and custodial accounts, while recent positive Phase 2 trial results and maintained "Buy" ratings from analysts like H.C. Wainwright and Stifel indicate ongoing interest in Inhibrx's potential.
Inhibrx Biosciences stock gains on insider buying and trial progress
Inhibrx Biosciences stock is gaining attention due to significant insider buying, with executives committing approximately USD 4.0 million to share purchases through September 16, 2026. This activity coincides with the company reporting encouraging Phase 2 data for its INBRX-106 antibody in head and neck cancer, showing an interim median progression-free survival of 9.6 months. The combination of insider confidence and positive clinical results provides a strong signal for investors.
Inhibrx Biosciences stock gains institutional support as Bank of America invests
Inhibrx Biosciences (INBX) stock has seen increased institutional investment, with Bank of America Corp DE disclosing a new $79.70 million stake and Tidal Investments LLC purchasing 10,170 shares. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $197.50, suggesting significant upside despite the risks inherent in clinical-stage biotechnology. The stock was trading at $109.35 on Nasdaq as of September 19, 2026.
Inhibrx (NASDAQ: INBX) director gets 10,000 options expiring 2036
Inhibrx (NASDAQ: INBX) director Kristiina Vuori, MD, was granted 10,000 stock options with an exercise price of $95.22, expiring on June 3, 2036. This amended Form 4 filing corrects an earlier administrative error regarding the option grant. The options become fully exercisable on June 3, 2027, contingent on her continued service.
Inhibrx (INBX) corrects director's 10,000-option grant
Inhibrx Biosciences (INBX) has filed an amended Form 4 to correct an earlier report regarding a director's stock option grant. The amendment specifies that director Kimberly Manhard was granted 10,000 stock options at an exercise price of $95.22 per share, vesting in 2027. This correction clarifies the number of options granted due to an administrative error in the initial filing.
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock By Investing.com
Inhibrx Biosciences director Jon Kayyem recently purchased 5,000 shares of the company's common stock for $500,000, at a price of $100 per share. This insider buying follows promising Phase 2 trial results for INBRX-106 and an expansion of the company's credit facility, though InvestingPro analysis suggests the stock is currently overvalued. The stock has seen a 295% surge over the past year despite recent volatility.
Inhibrx Biosciences Director Kimberly Manhard Revises Stock Option Grant Filing
Kimberly Manhard, a Director at Inhibrx Biosciences, Inc. (NASDAQ:INBX), submitted an amended Form 4/A to the SEC, correcting the number of stock options granted to her due to an administrative error. The filing confirms she received options for 10,000 shares of common stock at an exercise price of $95.22, granted on June 3, 2026. These options will vest fully on June 3, 2027, provided she continues her service, and will expire on June 3, 2036.
Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock
Jon Kayyem, a director at Inhibrx Biosciences, recently purchased 5,000 shares of the company's common stock for $500,000. This insider acquisition comes after the company announced positive Phase 2 trial results for its drug INBRX-106 in combination with Keytruda for head and neck cancer, leading to reiterated "Buy" ratings from H.C. Wainwright and Stifel. Despite the stock being considered overvalued by InvestingPro, its shares have surged significantly over the past year.
Inhibrx Biosciences (NasdaqGS:INBX) Stock Forecast & Analyst Predictions
Inhibrx Biosciences is projected to see significant growth in earnings (33.5% annually) and revenue (63.2% annually), with EPS expected to grow by 36.1% per annum. The company recently announced positive primary endpoint results from its Phase 2 HexAgon study for INBRX-106 in combination with pembrolizumab for HNSCC, showing a 48.3% objective response rate compared to 26.5% for pembrolizumab alone. Additionally, the FDA accepted the BLA for ozekibart in chondrosarcoma, setting a PDUFA date of April 14, 2027, marking a potential first commercial opportunity for the drug.
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com
Kimberly Manhard, a director at Inhibrx Biosciences, sold common stock worth $115,467 across two transactions on September 8 and 9, 2026. The sales occurred as the stock declined 8% over the past week, despite a 292% gain over the past year. Analysts maintain price targets significantly above the current trading price, while the company recently reported positive Phase 2 trial results for INBRX-106 and expanded its credit facility.
Inhibrx Biosciences director Kimberly Manhard sells $115,467 in stock By Investing.com
Kimberly Manhard, a director at Inhibrx Biosciences (NASDAQ: INBX), sold common stock worth $115,467 across two transactions on September 8 and 9, 2026. These sales, conducted through her revocable trust, occurred at prices between $115.14 and $115.795, while the stock has recently declined 8% but is up 292% over the past year. Analysts maintain high price targets despite the stock appearing overvalued according to InvestingPro, and the company recently reported positive Phase 2 trial results and expanded its credit facility.
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx announced positive interim results from its Phase 2 HexAgon study for INBRX-106 in Head and Neck Squamous Cell Carcinoma (HNSCC), showing a confirmed objective response rate of 48.3% and a median progression-free survival of 9.6 months when combined with pembrolizumab. The treatment, particularly effective in HPV+ patients, nearly doubled the response rate and significantly improved progression-free survival compared to pembrolizumab alone. Inhibrx plans to expand the study in HPV+ patients for a potential accelerated approval pathway and explore INBRX-106's use in other immunogenic tumors and cancer vaccine combinations.
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx Biosciences, Inc. will host a live webcast presentation on September 8, 2026, to announce primary endpoint results from the Phase 2 HexAgon study of INBRX-106. The study evaluates INBRX-106 in combination with pembrolizumab for first-line treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). The presentation will be accessible via webcast and their investor relations website.
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
Stifel has reiterated its Buy rating for Inhibrx Biosciences (INBX.US) and maintained a target price of $325. This indicates Stifel's continued positive outlook on the company's stock performance.
Inhibrx Biosciences (INBX) Earnings Put Its Valuation Back In Focus
Inhibrx Biosciences (INBX) reported a wider net loss in Q2 2026, yet its shares have seen significant gains year-to-date and over the last year. The company's negative price-to-book ratio of -27.5x indicates that its valuation is driven by future drug development potential rather than current net assets, due to liabilities exceeding assets. Investors are advised to consider both the potential rewards and risks, including clinical trial setbacks or equity dilution.
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com
Stifel has reiterated its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, noting a substantial upside from the current price. The firm's positive outlook is based on upcoming randomized durability data for INBRX-106, strong management insights into the drug's mechanism, and recent financial and regulatory progress including an expanded credit facility and the FDA's acceptance of ozekibart's Biologics License Application. Despite a significant 310% return over the past year, InvestingPro data suggests the shares may be overvalued.
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com
Stifel maintained its Buy rating on Inhibrx Biosciences (NASDAQ: INBX) with a $325.00 price target, despite the stock's significant 310% return over the past year and potential overvaluation. The firm anticipates strong potential ahead of randomized durability data for INBRX-106 next month and noted Inhibrx's recent credit facility expansion and FDA acceptance of its Biologics License Application for ozekibart, a potential first-in-class treatment for chondrosarcoma.
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX
Western Standard LLC has acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX), purchasing 47,000 shares valued at approximately $4.45 million, making it the fund's 19th largest holding. Despite this institutional interest, analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $150. Inhibrx Biosciences recently reported a quarterly loss of $2.34 per share, missing consensus estimates.
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Inhibrx Biosciences (NASDAQ:INBX) to a "strong sell" rating, despite a mixed outlook from other analysts, with the overall consensus remaining "Hold" and an average price target of $150. The company's shares opened at $88.37, significantly below its 12-month high, and it recently reported a quarterly loss that missed analyst expectations. Institutional investors hold a substantial stake in the company, with firms like Morgan Stanley and BlackRock among its major shareholders.
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?
Inhibrx Biosciences (INBX) reported widening net losses in Q2 2026, but also achieved significant clinical milestones including FDA acceptance of ozekibart's BLA for chondrosarcoma with a PDUFA date of April 14, 2027. The company is also anticipating Phase 2 data for INBRX-106 in head and neck squamous cell carcinoma. While these developments sharpen the investment narrative by providing clear catalysts, investors are reminded that the company's story still relies on capital access and execution, with a financing-related risk highlighted.
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?
Inhibrx Biosciences reported widening net losses in Q2 2026, alongside key clinical milestones including FDA acceptance of ozekibart's biologics license application with a PDUFA goal date of April 14, 2027, and upcoming Phase 2 data for INBRX-106. While these regulatory and clinical advancements are significant, the company's financial results and reliance on capital emphasize the ongoing risk-reward balance for investors. The article suggests that despite these milestones, the stock price might be too optimistic, urging investors to conduct thorough research.
Trading the Move, Not the Narrative: (INBX) Edition
This article provides an in-depth analysis of Inhibrx Biosciences Inc (INBX), highlighting strong sentiment across all time horizons and an exceptional 100.9:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide trading decisions.
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of warrants being subject to a 9.99% beneficial ownership limitation. The filing emphasizes the shared voting and dispositive power over these shares among the reporting group.
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole voting and dispositive power over these shares, which are held on behalf of its clients.
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss
Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating and a price target of $150.00, while institutional investors hold a significant 82.46% stake in the company.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages
Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired a new position worth approximately $78.3 million in the second quarter.
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS
Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's stock.
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com
This article reports on Inhibrx Biosciences Inc.'s Form 8K filing for August 13. The company's stock symbol INBX is mentioned with a performance of -8.91%. The content primarily serves as a placeholder or brief announcement from Investing.com.
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com
This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data
Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival benefit in chondrosarcoma and its biologics license application accepted by the FDA. Additionally, INBRX-106 showed positive interim Phase 2 HexAgon data in head and neck cancer, supporting further late-stage development.
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart
Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted Inhibrx's BLA for ozekibart (INBRX-109) for conventional chondrosarcoma, setting an April 14, 2027 PDUFA goal date, and the company initiated new Phase 1 colorectal cancer cohorts for ozekibart.
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"
Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per share, which was worse than analysts' expectations. Institutional ownership in INBX is substantial, with major investors like BlackRock and Morgan Stanley increasing their positions.
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday
Inhibrx Biosciences (INBX) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $2.28 per share, following a previous quarter where the company missed expectations with a $2.15 per share loss. The stock, which has seen significant volatility, currently holds an average "Hold" rating from analysts with a target price of $150.
(INBX) Volatility Zones as Tactical Triggers
This article analyzes Inhibrx Biosciences Inc Com (NASDAQ: INBX), highlighting positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, alongside multi-timeframe signal analysis with support and resistance levels.
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America
Bank of America Corporation has reported a beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, which represents 5.9% of the class. This ownership is held through various affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill Lynch Pierce Fenner & Smith, Inc., and U.S. Trust Co of Delaware. The filing indicates shared voting power over 857,306 shares and shared dispositive power over 857,318 shares, with no sole voting or dispositive power.
Inhibrx Biosciences Inc (INBX) Institutional Confidence
The article analyzes the institutional confidence score for Inhibrx Biosciences Inc (INBX), which currently stands at 7.00, placing it 80th in its industry. Institutional shareholding has increased to 84.51%, with Andreas Halvorsen being the largest shareholder. The report also lists other significant institutional shareholders and their recent activity.
Inhibrx Biosciences (INBX) Expands Its Credit Facility, Is The Valuation Risk Priced In?
Inhibrx Biosciences (INBX) recently expanded its credit facility to $500 million, leading to a reassessment of its valuation by investors, despite a strong year-to-date return. The company's high price-to-book ratio of 55.6x, compared to an industry average of 2.4x, reflects its negative equity and reliance on external borrowing. This situation highlights significant financing and balance sheet risks that investors need to consider carefully.
Inhibrx Biosciences Market Sentiment
The article provides a market sentiment overview for Inhibrx Biosciences (INBX), detailing analyst consensus, short interest, and recent analyst actions. Key signals indicate a "Buy" consensus from analysts with a significant upside on the price target, alongside a high short interest percentage. The analyst actions section lists various ratings and price target changes from firms like Stifel and JMP Securities.
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800
This article provides a comprehensive stock analysis of Inhibrx Biosciences Inc (INBX), highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite a predicted medium-term downtrend, multiple analysts rate it as "Buy" with a high price target, suggesting strong long-term prospects. The company is in a growing phase, though it has experienced a turnaround to a loss, and shows high institutional ownership.
